文献速递血脂与心血管预防心律失常

活动性癌症患者中NOAC与VKA预防和治疗血栓性疾病的有效性与安全性:随机对照试验的系统评价与Meta分析

[Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2020-01-01

在活动性癌症伴VTE患者中,NOAC降低VTE复发和非大出血性临床相关出血风险;在伴NVAF患者中两组结局无显著差异。

要点

  • 活动性癌症伴VTE患者中,NOAC较VKA降低VTE复发风险(RR=0.55)。
  • 活动性癌症伴VTE患者中,NOAC较VKA降低非大出血性临床相关出血风险(RR=0.77)。
  • 活动性癌症伴NVAF患者中,NOAC与VKA在VTE、卒中、出血及全因死亡上无显著差异。

核心结论

  • 对于伴有VTE的活动性癌症患者,NOAC在预防和治疗血栓性疾病方面可能较VKA更具疗效与安全性优势。
  • 对于伴有NVAF的活动性癌症患者,NOAC与VKA在降低VTE、卒中、出血及全因死亡事件上疗效相似。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Web of Science和Clinical Trials数据库截至2019年5月的随机对照试验,语种限中英文。
  • 共纳入9项RCT,其中活动性癌症伴VTE 5项、伴NVAF 4项。
  • 纳入文献质量较高(得分均>5分),各文献数据可汇总分析(P>0.05),主要结局事件异质性低(I2=0)。

主要发现

  • 活动性癌症伴VTE患者中,NOAC较VKA降低VTE复发风险(RR=0.55,95%CI 0.36~0.84,P=0.005)。
  • 活动性癌症伴VTE患者中,NOAC较VKA降低非大出血性临床相关出血风险(RR=0.77,95%CI 0.60~0.98,P=0.03)。
  • 活动性癌症伴NVAF患者中,NOAC与VKA在降低VTE、卒中、非大出血性临床相关出血、大出血及全因死亡事件上差异无统计学意义(P>0.05)。

关键数值与推荐

  • 活动性癌症伴VTE患者中,NOAC组VTE复发风险RR=0.55(95%CI 0.36~0.84,P=0.005)。
  • 活动性癌症伴VTE患者中,NOAC组非大出血性临床相关出血风险RR=0.77(95%CI 0.60~0.98,P=0.03)。
  • 活动性癌症伴NVAF患者中,NOAC与VKA各结局事件比较P>0.05。

临床怎么用

  • 活动性癌症合并VTE患者可优先考虑NOAC以降低VTE复发和非大出血性临床相关出血风险。
  • 活动性癌症合并NVAF患者中NOAC与VKA疗效和安全性相似,选择抗凝药需个体化评估。

局限性

  • 检索截止2019年5月,未纳入此后发表的研究。
  • 仅纳入中英文文献,可能存在语言偏倚。
  • 伴NVAF的RCT数量较少(4项),相关结论需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Object We aimed to compare the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonist (VKA) in the prevention and treatment of thrombotic diseases in patients with active cancer. Methods: To find randomized controlled trials (RCT) in which NOACs were compared VKAs in active cancer, we searched the electronic databases (PubMed, Web of Science and Clinical Trials) up to May 2019 and and languages restricted to Chinese and English. According to the screening strategy, two researchers independently screened and extracted literature, evaluated the quality of literature, the suitability of collected cross study data for analysis, and tested the heterogeneity. The relative risk (RR) and 95% confidence interval (95%CI) of major bleeding, clinically related non-major bleeding, VTE, stroke and all-cause mortality in active cancer patients with VTE, active cancer patients with non-valvular atrial fibrillation (NVAF) was calculated and the results were compared between NOAC with VKA. Results: A total of 9 RCTs were included, including 5 cancers with VTE (5/9) and 4 cancers with NVAF (4/9). A total of 5 867 patients were included. After excluding 1 818 (30.99%) patients with cancer history, 4 049 (68.86%) patients with active cancer were statistically analyzed. Among them, 2 278 (56.26%) received NOAC treatment, 1 771 patients (43.74%) received VKA treatment. The quality of the included documents was high (all scores were>5 points), and the data of each included document could be summarized and analyzed (P>0.05). The heterogeneity of main outcome events was very low (I2 = 0). In VTE patients with active cancer, NOACs were more effective in reducing recurrence of VTE (RR=0.55, 95%CI 0.36 -0.84; P = 0.005) and clinically related non-major bleeding (RR=0.77, 95%CI 0.60 -0.98; P = 0.03) than VKAs. In NVAF patients with active cancer, efficacy of NOACs and VKAs was similar in terms of reducing VTE, stroke, clinically related non-major bleeding, major bleeding and all-cause mortality events (P>0.05). Conclusions: For patients with active cancer accompanied by VTE, NOAC may has more advantages in efficacy and safety compared to VKA in the prevention and treatment of thrombotic diseases. 目的: 比较非维生素K拮抗剂口服抗凝药(NOAC)与传统维生素K拮抗剂(VKA)在活动性癌症患者中预防和治疗血栓性疾病的有效性和安全性。 方法: 在PubMed、Web of Science和Clinical Trials数据库中检索2019年5月前关于活动性癌症患者使用NOAC与VKA的随机对照试验(RCT)或原始研究设计为RCT的二次研究,语种限制为中、英文。由2名研究者依据筛选策略独立进行文献筛选与资料提取,评价文献质量,评估跨研究间数据汇总分析的适宜性,并检测主要结局事件异质性。比较NOAC与VKA在活动性癌症合并静脉血栓栓塞(VTE),或合并非瓣膜性心房颤动(NVAF)患者中,发生大出血、非大出血性临床相关出血、VTE、卒中和全因死亡的相对风险(RR)和95%置信区间(CI)。 结果: 共纳入9篇文献,4篇为原始研究,5篇为二次研究。其中活动性癌症伴VTE 5篇(5/9),伴NVAF 4篇(4/9)。共包含4 049例(68.86%)例活动性癌症患者,其中2 278例(56.26%)接受NOAC治疗,1 771例(43.74%)接受VKA治疗。纳入文献质量均较高(得分均≥5分),各纳入文献数据可进行汇总分析(P>0.05),结局事件异质性低(I2均<25%)。在活动性癌症伴VTE患者中,服用NOAC患者VTE复发(RR=0.55,95%CI:0.36~0.84,P=0.005)和非大出血性临床相关出血事件(RR=0.77,95%CI:0.60~0.98,P=0.03)风险低于VKA。在活动性癌症伴NVAF患者中,与VKA比较,NOAC在预防VTE和卒中、减少非大出血性临床相关出血事件、大出血及全因死亡上差异无统计学意义(P>0.05)。 结论: 对于伴有VTE或NVAF的活动性癌症患者,在预防和治疗血栓性疾病时,相对于VKA,NOAC在疗效与安全性方面更具优势。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang CX, Wu D, Yang PP, et al. [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 32847326. doi:10.3760/cma.j.cn112148-20200630-00529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。